NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
XTL Biopharmaceuticals Ltd (TA: XTLB)
XTLB Technical Analysis
4
As on 21st Nov 2024 XTLB STOCK Price closed @ 6.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.37 & Strong Buy for SHORT-TERM with Stoploss of 3.84 we also expect STOCK to react on Following IMPORTANT LEVELS. |
XTLBSTOCK Price
Open | 6.80 | Change | Price | % |
High | 6.80 | 1 Day | 0.00 | 0.00 |
Low | 6.30 | 1 Week | -0.40 | -5.63 |
Close | 6.70 | 1 Month | -2.20 | -24.72 |
Volume | 1758796 | 1 Year | 2.30 | 52.27 |
52 Week High 13.00 | 52 Week Low 3.10 |
TA Israel Most Active Stocks
TA125 | 2008.05 | 1.06% |
ORL | 92.30 | -5.04% |
BLRX | 10.50 | -25.00% |
CANF | 2.60 | -3.70% |
BEZQ | 520.00 | -2.71% |
ELAL | 846.50 | 1.46% |
LUMI | 4135.00 | 1.67% |
ICL | 1689.00 | 2.80% |
POLI | 4210.00 | 2.13% |
DSCT | 2394.00 | 1.79% |
TA Israel Top Gainers Stocks
TA Israel Top Losers Stocks
XTLB Daily Charts |
XTLB Intraday Charts |
Whats New @ Bazaartrend |
XTLB Free Analysis |
|
XTLB Important Levels Intraday
RESISTANCE | 7.66 |
RESISTANCE | 7.35 |
RESISTANCE | 7.16 |
RESISTANCE | 6.97 |
SUPPORT | 6.43 |
SUPPORT | 6.24 |
SUPPORT | 6.05 |
SUPPORT | 5.74 |
XTLB Forecast November 2024
4th UP Forecast | 8.82 |
3rd UP Forecast | 8.14 |
2nd UP Forecast | 7.72 |
1st UP Forecast | 7.3 |
1st DOWN Forecast | 6.1 |
2nd DOWN Forecast | 5.68 |
3rd DOWN Forecast | 5.26 |
4th DOWN Forecast | 4.58 |
XTLB Weekly Forecast
4th UP Forecast | 7.66 |
3rd UP Forecast | 7.35 |
2nd UP Forecast | 7.16 |
1st UP Forecast | 6.97 |
1st DOWN Forecast | 6.43 |
2nd DOWN Forecast | 6.24 |
3rd DOWN Forecast | 6.05 |
4th DOWN Forecast | 5.74 |
XTLB Forecast2024
4th UP Forecast | 33.87 |
3rd UP Forecast | 25.16 |
2nd UP Forecast | 19.77 |
1st UP Forecast | 14.38 |
1st DOWN Forecast | -0.98 |
2nd DOWN Forecast | -6.37 |
3rd DOWN Forecast | -11.76 |
4th DOWN Forecast | -20.47 |
XTL Biopharmaceuticals Ltd ( TA Israel Symbol : XTLB )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
XTLB Other Details
Segment | EQ | |
Market Capital | 64789956.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
XTLB Address
XTLB Latest News
XTLB Business Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Address: 5 Badner Street, Ramat Gan, Israel, 5218102
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service